SFGP
RANI icon

Stonebridge Financial Group (Pennsylvania)’s Rani Therapeutics RANI Stock Holding History

Stonebridge Financial Group (Pennsylvania)’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100
Closed -$126 – 773
2025
Q1 		$126 Hold
100
– – ﹤0.01% 973
2024
Q4 		$137 Buy
+100
New +$210 ﹤0.01% 814

Other funds holding RANI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Stonebridge Financial Group (Pennsylvania)'s RANI Position: Q2 2025 in Review

Stonebridge Financial Group (Pennsylvania) sold out of Rani Therapeutics (RANI) in Q2 2025, closing a stake of 100 shares — an estimated $126 sold.

Stonebridge Financial Group (Pennsylvania) first reported a position in RANI in Q4 2024 and held it in 2 quarters. The position peaked at $137 in Q4 2024. 39 funds tracked by Wall St. Rank hold RANI as of Q2 2025.

  • Stonebridge Financial Group (Pennsylvania) reported no remaining Rani Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Stonebridge Financial Group (Pennsylvania) sold 100 Rani Therapeutics shares in Q2 2025, an estimated $126.
  • Stonebridge Financial Group (Pennsylvania) first reported a position in Rani Therapeutics in Q4 2024 and held it in 2 quarters.
  • Stonebridge Financial Group (Pennsylvania)'s Rani Therapeutics position peaked at $137 in Q4 2024.
  • 39 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2025.

Based on Stonebridge Financial Group (Pennsylvania)'s 13F filing for Q2 2025, filed 24 Jul 2025.